Endocrinology Today—June 9, 2026

This week’s Endocrinology update highlights regulatory activity, diabetes technology progress, metabolic data releases, partnerships, and consumer health launches.

In Today’s Newsletter

Dive deeper

💊 Corcept Korlym data in T2D with hypercortisolism [1] [US • 06 Jun 2026]

https://www.businesswire.com/news/home/20260606758364/en/Corcept-Presents-New-Data-at-ADA-Improved-Outcomes-in-Patients-Receiving-a-GLP-1-with-Difficult-to-Control-Type-2-Diabetes-and-Hypercortisolism-Treated-with-Korlym
Context: Corcept Therapeutics presented CATALYST and MOMENTUM data at ADA’s 86th Scientific Sessions.
Key point: Korlym improved HbA1c and weight-related measures in CATALYST, with numerically greater benefit in patients also receiving GLP-1 receptor agonists or tirzepatide.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 Insulet Omnipod 6 and fully closed-loop AID data [2] [US • 06 Jun 2026]

https://www.businesswire.com/news/home/20260606260055/en/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care
Context: STRIVE evaluated Omnipod 6 in type 1 and type 2 diabetes, while EVOLUTION 3 evaluated a fully closed-loop system for adults with type 2 diabetes.
Key point: Omnipod 6 improved time in tight range and time in range versus Omnipod 5 in selected cohorts, while the fully closed-loop system improved time in range in type 2 diabetes.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Dexcom CONNECT supports CGM in non-insulin T2D [3] [US • 06 Jun 2026]

https://www.businesswire.com/news/home/20260606323066/en/Dexcom-CONNECT-Study-The-Most-Significant-Clinical-Study-Demonstrating-CGM-Benefits-for-People-with-Type-2-Diabetes-Not-Using-Insulin
Context: CONNECT randomized adults with type 2 diabetes not using insulin to Dexcom G7 or routine care with self-monitoring of blood glucose.
Key point: Dexcom G7 use led to clinically and statistically significant A1C reduction and improved glucose-control measures versus control over 26 weeks.
Implication: May influence prescriber choice and payer reviews pending full data.

✅ Tandem Control-IQ+ gains expanded CE mark [4] [EU • 05 Jun 2026]

https://www.businesswire.com/news/home/20260605572579/en/Tandem-Diabetes-Care-Automated-Insulin-Delivery-Systems-Receive-CE-Mark-for-Type-2-Diabetes-and-Type-1-Diabetes-During-Pregnancy
Context: Tandem Diabetes Care received CE mark expansion for t:slim X2 and Tandem Mobi with Control-IQ+ in Europe.
Key point: The expanded indications cover adults with type 2 diabetes and people with type 1 diabetes during pregnancy.
Implication: Introduces broader access that may affect clinical adoption and formulary pathways.

🩺 Glooko brings pump settings into EHR workflows [5] [05 Jun 2026]

https://www.businesswire.com/news/home/20260605285664/en/Glooko-Introduces-the-First-and-Only-Pump-Settings-EHR-Integration-to-Bring-Insulin-Pump-Data-Directly-Into-Clinical-Workflows
Context: Glooko introduced an Insulin Pump Settings EHR Integration in its Web 26.2 and Mobile 16.16 release.
Key point: The device-agnostic integration brings pump configuration data, such as basal schedules and insulin-to-carbohydrate ratios, into EHR flowsheets.
Implication: May expand screening, initiation, and follow-up at scale.

🤝 Breakthrough T1D and Sub-Zero Group Foundation partner [6] [US • 02 Jun 2026]

https://www.prnewswire.com/news-releases/breakthrough-t1d-and-sub-zero-group-foundation-announce-national-partnership-to-support-type-1-diabetes-research-302788852.html
Context: Breakthrough T1D, formerly JDRF, announced a national partnership with Sub-Zero Group Foundation.
Key point: The partnership will support type 1 diabetes research, awareness, and work across early detection, disease-modifying therapies, technology, complications, and cell therapies.
Implication: Signals pipeline investment and modality expansion.

🌿 Lemme Balance targets hormone and ovarian health [7] [01 Jun 2026]

https://nutraceuticalbusinessreview.com/lemme-balance-capsules-hormone-ovarian-pcos-pmos
Context: Lemme launched Balance Capsules as PCOS is reframed as polyendocrine metabolic ovarian syndrome, or PMOS.
Key point: The supplement contains Myo-Inositol and D-Chiro-Inositol in a 40:1 ratio, plus 5-MTHF, chromium picolinate, vitamin D3, and spearmint leaf extract.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🧬 Boan Biotech submits denosumab biosimilar BLA [8] [US • 04 Jun 2026]

https://www.bigmoleculewatch.com/2026/06/04/boan-biotech-submits-bla-to-fda-for-two-denosumab-biosimilars/
Context: Boan Biotech submitted a BLA to FDA for BA6101 and BA1102, denosumab biosimilars referencing Prolia and Xgeva.
Key point: The submission seeks approval for indications tied to osteoporosis-related conditions and bone metastasis-related conditions, among others.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

ADA 2026 diabetes-technology updates point to broader automation, lower user burden, and expanded populations for AID and CGM.
Type 2 diabetes remains a major focus, spanning non-insulin CGM, automated insulin delivery, EHR workflow integration, and adjunct metabolic treatment.
Regulatory and access signals are moving in parallel, including CE mark expansion for Tandem and a US biosimilar BLA from Boan Biotech.
Women’s metabolic and hormonal health is attracting consumer-health product activity, with PMOS framing used to position new nutraceutical launches.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did Corcept report for Korlym in CATALYST?

Corcept said Korlym improved HbA1c and weight-related measures in patients with difficult-to-control type 2 diabetes and hypercortisolism. The ADA update highlighted patients also taking GLP-1s or tirzepatide. [1]

What is Insulet’s Omnipod 6?

Omnipod 6 is Insulet’s investigational next-generation tubeless AID system. STRIVE data showed improved glycemic measures versus Omnipod 5 in selected cohorts. [2]

What population did Dexcom CONNECT study?

CONNECT studied adults with type 2 diabetes not using insulin. Dexcom said G7 improved A1C and glucose-control measures versus routine care with self-monitoring over 26 weeks. [3]

What did Tandem’s CE mark expansion cover?

The expanded CE mark covers Tandem t:slim X2 and Tandem Mobi with Control-IQ+ for adults with type 2 diabetes and type 1 diabetes during pregnancy. [4]

What does Glooko’s new EHR integration do?

Glooko’s integration brings insulin pump settings into EHR flowsheets, including basal rates, insulin-to-carbohydrate ratios, correction factors, active insulin time, and closed-loop status. [5]

What did Boan Biotech submit to FDA?

Boan Biotech submitted a BLA for BA6101 and BA1102, denosumab biosimilars referencing Prolia and Xgeva. The filing supports potential US commercialization. [8]

Entities / Keywords

Corcept Therapeutics, Korlym, mifepristone, CATALYST, MOMENTUM, hypercortisolism, difficult-to-control type 2 diabetes, GLP-1, tirzepatide
Insulet, Omnipod 6, Omnipod 5, STRIVE, EVOLUTION 3, EVOLVE, fully closed-loop AID, type 1 diabetes, type 2 diabetes
Dexcom, Dexcom G7, CONNECT, CGM, continuous glucose monitoring, type 2 diabetes not using insulin
Tandem Diabetes Care, t:slim X2, Tandem Mobi, Control-IQ+, CE mark, CIRCUIT, 2IQP
Glooko, Insulin Pump Settings EHR Integration, EHR flowsheets, pump settings, SmartText-style workflows
Breakthrough T1D, JDRF, Sub-Zero Group Foundation, type 1 diabetes research
Lemme, Lemme Balance Capsules, PCOS, PMOS, Myo-Inositol, D-Chiro-Inositol, 5-MTHF
Boan Biotech, BA6101, BA1102, denosumab, Prolia, Xgeva, biosimilar, FDA BLA